Published in Parasitol Res on January 01, 1994
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med (2006) 2.60
Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother (2006) 1.48
Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun (2000) 1.44
DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother (2001) 1.39
Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother (2001) 1.39
Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother (1999) 1.25
Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother (2001) 1.16
Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. Antimicrob Agents Chemother (2007) 1.15
Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate. Antimicrob Agents Chemother (1998) 1.12
ABC proteins of Leishmania. J Bioenerg Biomembr (2001) 1.00
Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis. Infect Immun (2002) 0.80
In Vitro Sensitivity of Cutaneous Leishmania Promastigote Isolates Circulating in French Guiana to a Set of Drugs. Am J Trop Med Hyg (2017) 0.75
Herbal extract targets in Leishmania tropica. J Parasit Dis (2014) 0.75
Post-kala-azar dermal leishmaniasis. Lancet Infect Dis (2003) 3.63
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology (1999) 3.03
A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol (1998) 2.94
Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg (1993) 2.93
Detection of antibodies to variant antigens on Plasmodium falciparum-infected erythrocytes by flow cytometry. Cytometry (1999) 2.87
In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest (1993) 2.84
Detection of very low level Plasmodium falciparum infections using the nested polymerase chain reaction and a reassessment of the epidemiology of unstable malaria in Sudan. Am J Trop Med Hyg (1996) 2.72
Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect (2001) 2.50
Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg (1994) 2.45
Primary aspergilloma of paranasal sinuses in the Sudan. A review of seventeen cases. Br J Surg (1969) 2.35
Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun (1999) 2.16
Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother (1991) 2.09
Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. J Med Chem (1998) 2.06
Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg (2001) 2.00
Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections. Immunol Lett (2000) 1.89
Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilms. Infect Immun (1990) 1.81
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother (1999) 1.77
Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis (2000) 1.76
Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. Infect Immun (2001) 1.69
IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol (1995) 1.69
Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg (2001) 1.65
Anti-phospholipid antibodies in patients with Plasmodium falciparum malaria. Immunology (1993) 1.64
Development and application of the polymerase chain reaction for the detection and identification of Leishmania parasites in clinical material. Arch Inst Pasteur Tunis (1995) 1.63
Immunological features of kala-azar. Am J Trop Med Hyg (1978) 1.61
Nine-year longitudinal study of antibodies to variant antigens on the surface of Plasmodium falciparum-infected erythrocytes. Infect Immun (1999) 1.59
Increased plasma concentrations of sICAM-1, sVCAM-1 and sELAM-1 in patients with Plasmodium falciparum or P. vivax malaria and association with disease severity. Immunology (1994) 1.55
The epidemiology of febrile malaria episodes in an area of unstable and seasonal transmission. Trans R Soc Trop Med Hyg (2001) 1.53
Further observations on the primary paranasal aspergillus granuloma in the Sudan: a morphological study of 46 cases. Am J Trop Med Hyg (1973) 1.53
Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun (1990) 1.51
Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun (1993) 1.50
Seasonal changes in the Plasmodium falciparum population in individuals and their relationship to clinical malaria: a longitudinal study in a Sudanese village. Parasitology (1998) 1.48
Evaluation of the efficacy of Iran leishmanin and comparison with leishmanins from Wellcome (UK) and Roma (Italy) in cured cutaneous leishmaniasis patients. Trans R Soc Trop Med Hyg (1994) 1.45
Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated Plasmodium falciparum malaria. Infect Immun (1997) 1.45
Transient depletion of T cells with high LFA-1 expression from peripheral circulation during acute Plasmodium falciparum malaria. Eur J Immunol (1991) 1.44
Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun (2001) 1.44
Evidence of endothelial inflammation, T cell activation, and T cell reallocation in uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg (1994) 1.42
Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg (1995) 1.41
Random amplified polymorphic DNA for the differentiation of Leishmania donovani isolates from Sudan. Trans R Soc Trop Med Hyg (1996) 1.41
High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin Exp Immunol (1998) 1.40
Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun (2000) 1.39
Pseudomonas aeruginosa exoproteases inhibit human neutrophil chemiluminescence. Infect Immun (1984) 1.37
Effect of cyclosporin A on human neutrophil and monocyte function. Scand J Immunol (1985) 1.35
Interaction of Pseudomonas aeruginosa alkaline protease and elastase with human polymorphonuclear leukocytes in vitro. Infect Immun (1984) 1.34
The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS (2000) 1.33
A new portable device for automatic controlled-gradient cryopreservation of blood mononuclear cells. J Immunol Methods (1993) 1.29
1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine (1992) 1.29
Increased plasma levels of soluble ICAM-1 and ELAM-1 (E-selectin) during acute Plasmodium falciparum malaria. Immunol Lett (1993) 1.25
Chronic Plasmodium falciparum infections in an area of low intensity malaria transmission in the Sudan. Parasitology (2000) 1.25
Structure-activity studies: in vitro antileishmanial and antimalarial activities of anthraquinones from Morinda lucida. Planta Med (1999) 1.24
Eleven years of malaria surveillance in a Sudanese village highlights unexpected variation in individual disease susceptibility and outbreak severity. Parasitology (2004) 1.23
Direct agglutination test for diagnosis and sero-epidemiological survey of kala-azar in the Sudan. Trans R Soc Trop Med Hyg (1992) 1.22
Blood monocyte and neutrophil functions in the acquired immune deficiency syndrome. Scand J Immunol (1986) 1.22
Overlapping antigenic repertoires of variant antigens expressed on the surface of erythrocytes infected by Plasmodium falciparum. Parasitology (1999) 1.21
Virulence factors of Pseudomonas aeruginosa. Antibiot Chemother (1971) (1987) 1.21
The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. J Infect Dis (1997) 1.18
The roles of the pfcrt 76T and pfmdr1 86Y mutations, immunity and the initial level of parasitaemia, in predicting the outcome of chloroquine treatment in two areas with different transmission intensities. Ann Trop Med Parasitol (2005) 1.17
Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob Agents Chemother (2001) 1.17
Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax (2009) 1.17
Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob Agents Chemother (1994) 1.16
Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol (1994) 1.16
Loss of cellular immune reactivity during acute Plasmodium falciparum malaria. FEMS Microbiol Immunol (1991) 1.15
Seasonal variation in agglutination of Plasmodium falciparum-infected erythrocytes. Am J Trop Med Hyg (1998) 1.15
Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania. Antimicrob Agents Chemother (1993) 1.14
Suppression of parasite-specific response in Plasmodium falciparum malaria. A longitudinal study of blood mononuclear cell proliferation and subset composition. Scand J Immunol (1986) 1.14
Recognition of Leishmania antigens by T lymphocytes from nonexposed individuals. Infect Immun (1992) 1.13
Early immune response in susceptible and resistant mice strains with chronic Pseudomonas aeruginosa lung infection determines the type of T-helper cell response. APMIS (1999) 1.12
The use of a water-soluble formazan complex to quantitate the cell number and mitochondrial function of Leishmania major promastigotes. Parasitol Res (1994) 1.12
Interferon-gamma- and tumour necrosis factor-alpha-producing cells in humans who are immune to cutaneous leishmaniasis. Scand J Immunol (1999) 1.11
The polymerase chain reaction can reveal the occurrence of naturally mixed infections with Leishmania parasites. Acta Trop (1994) 1.11
Lymphocyte response to purified Plasmodium falciparum antigens during and after malaria. Acta Trop (1986) 1.11
Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob Agents Chemother (1994) 1.11
Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol (1999) 1.10
The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Immunol Today (1996) 1.10
The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Antimicrob Agents Chemother (1995) 1.10
Soluble Plasmodium falciparum antigens contain carbohydrate moieties important for immune reactivity. J Clin Microbiol (1987) 1.09
Enhanced inhibition of in vitro multiplication of Plasmodium falciparum by stimulated human polymorphonuclear leucocytes. Clin Exp Immunol (1984) 1.09
Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. Clin Exp Immunol (1994) 1.08
Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin Exp Immunol (2002) 1.08
Evaluation of the polymerase chain reaction in the diagnosis of cutaneous leishmaniasis due to Leishmania major: a comparison with direct microscopy of smears and sections from lesions. Trans R Soc Trop Med Hyg (1996) 1.07
Clinical pattern of severe Plasmodium falciparum malaria in Sudan in an area characterized by seasonal and unstable malaria transmission. Trans R Soc Trop Med Hyg (2005) 1.07
Elastase from polymorphonuclear leucocytes: a regulatory enzyme in immune complex disease. Clin Exp Immunol (1986) 1.07
Inhibition of human natural killer cell activity by Pseudomonas aeruginosa alkaline protease and elastase. Infect Immun (1987) 1.07